Background Medullary thyroid carcinoma (MTC) originates in the thyroid C cells, accounting
for 5% to 10% or all thyroid malignancies. Approximately 75% of cases are sporadic …

Medullary thyroid carcinoma (MTC), an uncommon neoplasm stemming from the calcitonin-
producing thyroid parafollicular C cells, accounts for approximately 3% to 5% of cases of …

Medullary thyroid carcinoma (MTC) is a rare thyroid malignancy. About 75% are sporadic
(sMTC) while the remaining 25% are hereditary (hMTC). The treatment of choice for both …

Medullary thyroid carcinoma (MTC) accounts for 5–8% of all thyroid cancers. MTC is mainly
sporadic in nature, but an hereditary pattern [multiple endocrine neoplasia type 2 (MEN 2)] is …

Medullary thyroid carcinoma (MTC) is a rare malignancy of the thyroid C cells. It occurs in
hereditary (25% of cases) and sporadic forms, and aggressiveness is related to the clinical …

Medullary thyroid carcinoma (MTC) arises from parafollicular or C cells that produce
calcitonin (CT), and accounts for 5–10% of all thyroid cancers. MTC is hereditary in about …

Medullary thyroid carcinoma (MTC) is a prototype disease in the rapidly emerging field of
molecular endocrine oncology. Since its recognition in 1959, MTC has distinguished itself …

Objective This review outlines advances in the diagnosis, genetic testing, and progress in
medullary thyroid cancer (MTC) treatment in light of the most recent evidence. Methods …

This article summarizes the major clinical, pathological, and molecular features of medullary
thyroid carcinoma (MTC), based on a review of the most significant advances in our …

Recent advances in the diagnosis and treatment of medullary thyroid carcinoma (MTC) have
been significant, but some issues remain controversial. MTC may occur either as a …